دوره 17، شماره 1 - ( 10-1404 )                   جلد 17 شماره 1 صفحات 96-90 | برگشت به فهرست نسخه ها

XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mousavi S N, Khademolhosseini A, Fattahi M J, khansalar S, Tahmasebi S, Ghaderi A et al . Interleukin-38 serum levels in breast cancer: A comparative analysis of women under 40 and over 50. Caspian J Intern Med 2026; 17 (1) :90-96
URL: http://caspjim.com/article-1-4633-fa.html
Interleukin-38 serum levels in breast cancer: A comparative analysis of women under 40 and over 50. . 1404; 17 (1) :90-96

URL: http://caspjim.com/article-1-4633-fa.html


چکیده:   (111 مشاهده)
Background: Interleukin-38 (IL-38) is an anti-inflammatory cytokine with immunomodulatory properties, but its role in breast cancer (BC) is unclear. This study aimed to evaluate IL-38 serum levels in BC patients aged ≤40 and ≥50 years and to correlate the findings with clinicopathological features.
Methods: IL-38 levels were measured using an enzyme-linked immunosorbent assay (ELISA) in the serum of 30 BC patients aged ≤40, 30 aged ≥50, and 30 healthy controls.  Non-parametric tests were used for statistical comparisons, and Spearman's correlation was used to examine the correlation between IL-38 and age and tumor size.
Results: There was no significant difference in serum IL-38 levels between patients aged ≥50 and those aged ≤40 or their age-matched controls. However, patients aged ≤40 years had significantly lower IL-38 levels than healthy individuals of the same age (P=0.003). In addition, serum IL-38 levels were significantly different between healthy individuals aged ≤40 and ≥50 years. Patients with stage I and II BC had significantly lower serum IL-38 levels than healthy controls (P=0.04 and P=0.003, respectively).  However, there were no significant associations between IL-38 serum levels and histological grade (P=0.09), nuclear grade (P=0.11), lymphovascular invasion (P=0.72), perineural invasion (P=0.21), lymph node involvement (P=0.71) and tumor size (P=0.70).
Conclusion: Our results suggest that any change in IL-38 serum levels is likely to affect the anti-inflammatory response in BC patients, especially those under 40 years of age. However, this is a preliminary study, and further studies with larger cohorts are needed to validate these findings.

 
متن کامل [PDF 422 kb]   (29 دریافت)    
نوع مطالعه: Original Article | موضوع مقاله: Imonology
دریافت: 1403/10/4 | پذیرش: 1404/1/17 | انتشار: 1404/11/1

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2026 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by : Yektaweb